Glasgow biopharma Mironid Secures $39.9 Million in Latest Series B Funding Round

Glasgow biopharma Mironid secured $39.9 million in its latest Series B, adding another data point to the FinTech funding market.

Glasgow biopharma Mironid Raises $39.9 million in Funding

Glasgow biopharma Mironid raises €39.9 million Series B. ADPKD is a hereditary disorder caused predominantly by mutations in the PKD1 or PKD2 gene, leading to the uncontrolled growth of fluid-filled cysts in the kidneys and, in many cases, eventual kidney failure.

Investors Behind the Funding

The round was backed by Scottish National Investment Bank. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Glasgow biopharma Mironid operates in FinTech. Glasgow biopharma Mironid's financing adds to recent private-market activity.

Strategic Use of Funds

Develop treatments for Autosomal Dominant Polycystic Kidney Disease.

Looking Ahead

Glasgow biopharma Mironid raises €39.9 million Series B

Source reference: original announcement/article.